AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Alpha Tau Medical Ltd. posted a net loss per share of $0.26 for the first quarter of 2026, marking a significant deterioration from the same period a year earlier as the clinical-stage oncology company continues to advance its radiation therapy technology. The Israeli-American firm, which trades on the Nasdaq under ticker DRTS, remains in the development and commercialization phase of its diffusing alpha-emitters radiation therapy platform known as Alpha DaRT.
The bottom line showed a net loss of $22.9M for the quarter. Year-over-year, the per-share loss widened to $0.26 from $0.12 in the first quarter of 2025, representing a 116.7% increase in the loss as the company burns through capital to fund its clinical programs and push toward potential regulatory approvals.
Despite the mounting losses typical of pre-revenue biotech companies, Wall Street analysts maintain a constructive view on Alpha Tau’s prospects. The current consensus stands at 4 buy ratings and 2 hold ratings, with no sell recommendations among covering analysts. The company’s Alpha DaRT technology represents a novel approach in the oncology therapeutics space, using alpha radiation to target solid tumors, though it has yet to generate meaningful revenue from commercialization.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
